Corporate Breaking News
Corporate Breaking News
Home : FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
Sep 14
2020

FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis

TARRYTOWN, N.Y. and PARIS, Sept. 14, 2020 /PRNewswire/ -- Designation based on positive results from Part A of pivotal Phase 3 trial Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic...
Source:https://www.prnewswire.com:443/news-releases/fda-grants-dupixent-dupilumab-breakthrough-therapy-designation-for-eosinophilic-esophagitis-301129713.html
 
Related News
» Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine
» Tropical Storm Sally expected to hit Gulf Coast as slow-moving hurricane
Home
About us
Archive
Sitemap
Powered By Corporate Breaking News.com Home| About us| Archive News| Sitemap